• Publications
  • Influence
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
TLDR
An international TLS consensus expert panel of paediatric and adult oncologists, experts in TLS pathophysiology and experts in encryption, developed a final model of low, intermediate and high risk TLS classification and associated TLS prophylaxis recommendations. Expand
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
TLDR
The overall improvement over the results in ALL-BFM 86 (6-year EFS, 72%; P =. 001) was based on fewer recurrences among patients in the MRG with B-cell-precursor ALL, indicating an advantage of more condensed induction therapy. Expand
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
TLDR
It is concluded that, with intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines 240 mg/m(2) and cyclophosphamide (3 g/ m(2)) and moderate-dose prophylactic cranial irradiation but no local radiotherapy, an event-free survival rate of 90% can be achieved in childhood T-LBL. Expand
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
TLDR
Infants with PGR, comprising a major subgroup among infants, might successfully be treated with conventional therapy, whereas PPR require new therapeutic strategies, including early treatment intensification or bone marrow transplantation in first remission. Expand
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
TLDR
This therapy strategy provided patients of all NHL subtypes with an equally high chance to survive event-free, except patients with PTCL, in which three of four patients suffered from relapse. Expand
Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.
TLDR
Considering the high-survival rate of this large unselected ALL cohort, the risk of SN is relatively low, though higher, especially after cranial irradiation, than in the general population. Expand
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
TLDR
In trial ALL-BFM 86, the largest multicenter trial of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia, treatment response was used as an overriding stratification factor for the first time and the benefit of intensive reinduction therapy even for low-risk patients was confirmed. Expand
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
TLDR
The 6-year event-free survival (pEFS) of patients with abdominal stage III and LDH >/=500 U/L was 81% +/- 4% as compared with 43% +/- 10% in study 86, and of 26 CNS(+) patients, 5 died early, but only 3 relapsed. Expand
Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.
TLDR
The methotrexate schedule of the NHL-BFM90 protocol including IT therapy can be safely replaced by a less toxic schedule of metotrexate 3 g/m2 in a 3-hour infusion without IT therapy. Expand
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995
TLDR
While it has proven so far to be impossible to improve the outcome for the small group of high risk patients, the number of recurrences could be effectively reduced for the large group of patients responding adequately to the prednisone in vivo sensitivity test. Expand
...
1
2
3
4
5
...